Biotech Holdings Ltd (OTCBB:BIOHF) die neue Perle in Sachen DIABETIS - 500 Beiträge pro Seite

[js200]

Biotech Holdings finalizes plans for launch of Sucanon diabetes drug in Mexico

Wednesday, March 31, 2004 09:01 ET

VANCOUVER, Mar 31, 2004 /PRNewswire-FirstCall via COMTEX/ -- Robert Rieveley, President of Biotech Holdings (the "Company", TSX-VEN: BIO.V; OTC BB: BIOHF) announced that the Company is finalizing plans for the launch in Mexico of its diabetes drug, Sucanon.

"We are now discussing, with a Mexican marketing partner, the details of an agreement for distribution of Sucanon to national pharmacy chains in Mexico, combined with medical symposia to deliver information about Sucanon therapy to doctors and pharmacists. At the same time, to make the Mexican public aware of the benefits of Sucanon, we are planning extensive advertising of Sucanon on television and radio throughout Mexico," Mr. Rieveley said.

"Our goal is a national launch of Sucanon in Mexico. Accordingly, together with reaching doctors and pharmacists with medical information about Sucanon, we are planning to simultaneously make the public aware, through television and radio advertising, that Sucanon, an important new drug for treatment of Type II symptoms, is now available through pharmacy chains in all regions of Mexico," Mr. Rieveley said.

"World Health Organization data indicate that over 14% of Mexican adults suffer from Type II Diabetes. With a population of over 110 million, Mexico is accordingly one of the largest markets in the world for Type II Diabetes drugs. In terms of the number of Type II diabetics, Mexico City alone has more than all of Canada," Mr. Rieveley noted.

Biotech Holdings` Sucanon is a new drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance.

The drug is an insulin-receptor sensitizer, a class of drugs for controlling the chronically high blood sugar levels that typify diabetes by improving the receptivity of the cell wall to glucose uptake. The drug, in tablet form, works by improving patients` ability to utilize insulin, the hormone that controls blood sugar levels. Type II Diabetes affects more than 18 million people in North America, over 30 million in Latin America and nearly 200 million worldwide.

Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil.

If you would you would like to be added to Biotech Holdings` email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp

Biotech Holdings Ltd.`s head office is in Richmond, British Columbia. Biotech Holdings` shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at [e-mail]. For background information and current stock quotations, please visit Biotech`s website at www.biotechltd.com.





SOURCE Biotech Holdings Ltd.


CONTACT: For inquiries, contact Austin Rand at Biotech Holdings Ltd.,
1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at
[e-mail]. For background information and current stock quotations,
please visit Biotech`s website at www.biotechltd.com.
To request a free copy of this organization`s annual report, please go to
http://www.newswire.ca and click on reports@cnw.
(BIO. BIOHF)

http://www.prnewswire.com



JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


03/31/2004 (09:01 ET) Biotech Holdings finalizes plans for launch of Sucanon diabetes drug in Mexico - PR Newswire



03/24/2004 (08:47 ET) Market Pulse Breaking News Alert for Wednesday, March 24, 2004: EBOI -- Enhance Biotech, Inc. Selects Covance to Advance Clinical Research of Its Psoriasis Treatment! - Internet Wire



03/23/2004 (17:39 ET) TSX Venture Exchange closes at 1,854.16 down 12.76 points - The Canadian Press (AP)



03/23/2004 (11:11 ET) Wall Street News Alert: Stock Focus List! March 23, 2004 - M2 Communications



03/22/2004 (14:09 ET) BIOHF: Reported on by Emerging Stock Report - Knobias



03/22/2004 (13:49 ET) Emerging Stock Report: Emerging Stock Report, announces "daily stock picks" - M2 Communications



03/22/2004 (11:03 ET) Financial Relations Inc: HotStockChat.com reports on Stocks of Interest and Stocks on the Move on the OTCBB for March 22, 2004 - M2 Communications



03/22/2004 (04:26 ET) PennyPicks.com: PennyPicks` OTCBB Monday`s Volume, Price Gainers PLUS Tuesday`s Stock Watch - M2 Communications



03/19/2004 (09:00 ET) Biotech Holdings Sucanon drug facility on schedule for completion - PR Newswire



03/17/2004 (10:24 ET) Wall Street News Alert: Primetime Stock Watch! March 17, 2004, Part 4 - M2 Communications



03/12/2004 (03:19 ET) Emerging Stock Report: Emerging Stock Report announces this mornings "stocks to watch" - M2 Communications



03/11/2004 (17:50 ET) TSX Venture Exchange closes at 1,869.44 down 26.51 points - The Canadian Press (AP)



03/11/2004 (11:34 ET) Financial Relations Inc: HotStockChat.com reports on Stocks of Interest and Stocks on the Move on the OTCBB for March 11, 2004 - M2 Communications



03/11/2004 (09:00 ET) Biotech holdings retains Stockgroup Media for investor awareness program - PR Newswire


JS200

[cwn]

"World Health Organization data indicate that over 14% of Mexican adults suffer from Type II Diabetes."

Tja, und wie viele Mexikaner können sich überhaupt einen Arztbesuch oder Medikamente leisten?

Die Marktchancen dürften dort relativ "begrenzt" sein...

[js200]

@CWN

Wo steht, dass es nur bei den Mexikaner bleibt ?????

JS200

[js200]

Last Trade: 0.670 Change: 0.000 (+0.000%)
Previous Close: 0.670 Volume: 313,100
Bid: 0.670 Ask: 0.690
Today`s Open: 0.685 # of Trades: 92

Day High: 0.695 Day Low: 0.660
52 Week High: 0.768 52 week Low: 0.021
Market Cap: N/A Avg Daily Vol: N/A
EPS: -0.02 PE Ratio: -33.500
Dividend: N/A Yield: N/A

JS200

[js200]

Last Trade: 0.910 Change: 0.130 (+16.667%)
Previous Close: 0.780 Volume: 1,894,800
Bid: 0.870 Ask: 0.910
Today`s Open: 0.810 # of Trades: 536


Läuft und läuft, hmmmmmmmm !!!!!!!

JS200

[fonx]

Wie kommt denn sowas zustande?FONX

[js200]

@FONX

Ich hab dir doch geschrieben, ich habe eine Zweite LAMP

JS200

[fonx]

Haste da noch was vor? Würde mich nicht wundern,FONX

[fonx]

Hmmmmmmmm,ne zweite Lamp,jetzt muss erst mal die erste laufen,FONX

[js200]

04/07/2004 (03:52 ET) StockGrid.com: Stock Watch List for Friday, April 9, 2004: BIOHF, BKYI - M2 Communications
03/31/2004 (09:01 ET) Biotech Holdings finalizes plans for launch of Sucanon diabetes drug in Mexico - PR Newswire
03/24/2004 (08:47 ET) Market Pulse Breaking News Alert for Wednesday, March 24, 2004: EBOI -- Enhance Biotech, Inc. Selects Covance to Advance Clinical Research of Its Psoriasis Treatment! - Internet Wire
03/23/2004 (17:39 ET) TSX Venture Exchange closes at 1,854.16 down 12.76 points - The Canadian Press (AP)
03/23/2004 (11:11 ET) Wall Street News Alert: Stock Focus List! March 23, 2004 - M2 Communications

JS200

[js200]

04/12/2004 (17:58 ET) TSX Venture Exchange closes at 1,872.64 down 12.18 points - The Canadian Press (AP)
04/07/2004 (03:52 ET) StockGrid.com: Stock Watch List for Friday, April 9, 2004: BIOHF, BKYI - M2 Communications
03/31/2004 (09:01 ET) Biotech Holdings finalizes plans for launch of Sucanon diabetes drug in Mexico - PR Newswire
03/24/2004 (08:47 ET) Market Pulse Breaking News Alert for Wednesday, March 24, 2004: EBOI -- Enhance Biotech, Inc. Selects Covance to Advance Clinical Research of Its Psoriasis Treatment! - Internet Wire
03/23/2004 (17:39 ET) TSX Venture Exchange closes at 1,854.16 down 12.76 points - The Canadian Press (AP)


JS200

[js200]

Last Trade: 0.830 Change: -0.030 (-3.488%)
Previous Close: 0.860 Volume: 374,700
Bid: 0.825 Ask: 0.850
Today`s Open: 0.885 # of Trades: 139


JS200

[js200]

Biotech Holdings readies first production run of Sucanon Diabetes drug

Wednesday, April 14, 2004 09:01 ET

VANCOUVER, Apr 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) has announced that installation of pharmaceutic processing equipment required for Sucanon production is currently being completed.

"Sucanon production is scheduled to begin within the week; our first production run is for 1.2 million Sucanon tablets, sufficient for 20,000 one-month Sucanon treatment packages. There are 60 tablets in each one-month treatment regimen," Mr. Rieveley said.

"A portion of this initial production is being allocated for marketing purposes, including distribution through symposia for introducing Sucanon to doctors, pharmacists and clinics in Mexico. The bulk of the first production of tablets however will be shipped for sale by our marketers in Mexico and the start of Sucanon revenues for Biotech," Mr. Rieveley said.

World Health Organization data indicate that over 14% of Mexican adults suffer from Type II Diabetes. With a population of over 110 million, Mexico is one of the largest markets in the world for Type II Diabetes drugs.

Biotech Holdings` Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients` ability to utilize insulin, the hormone that controls blood sugar levels. Type II Diabetes affects more than 18 million people in North America, over 30 million in Latin America and nearly 200 million worldwide.

Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil.

If you would you would like to be added to Biotech Holdings` email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp

Biotech Holdings Ltd.`s head office is in Richmond, British Columbia. Biotech Holdings` shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at [e-mail]. For background information and current stock quotations, please visit Biotech`s website at www.biotechltd.com.

SOURCE Biotech Holdings Ltd.


CONTACT: Austin Rand at Biotech Holdings Ltd., 1-888-216-1111
(toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at
[e-mail]. For background information and current stock quotations,
please visit Biotech`s website at www.biotechltd.com.
(BIO. BIOHF)

http://www.prnewswire.com



Copyright (C) 2004 PR Newswire. All rights reserved.


-0-


KEYWORD: British Columbia
INDUSTRY KEYWORD: MTC
OTC


STOCK SYMBOLS: [(bio.)] [(biohf)]


JS200

[js200]

04/14/2004 (09:01 ET) Biotech Holdings readies first production run of Sucanon Diabetes drug - PR Newswire
04/12/2004 (17:58 ET) TSX Venture Exchange closes at 1,872.64 down 12.18 points - The Canadian Press (AP)
04/07/2004 (03:52 ET) StockGrid.com: Stock Watch List for Friday, April 9, 2004: BIOHF, BKYI - M2 Communications
03/31/2004 (09:01 ET) Biotech Holdings finalizes plans for launch of Sucanon diabetes drug in Mexico - PR Newswire
03/24/2004 (08:47 ET) Market Pulse Breaking News Alert for Wednesday, March 24, 2004: EBOI -- Enhance Biotech, Inc. Selects Covance to Advance Clinical Research of Its Psoriasis Treatment! - Internet Wire

JS200

[js200]

Last Trade: 0.880 Change: 0.050 (+6.024%)
Previous Close: 0.830 Volume: 175,000
Bid: 0.880 Ask: 0.900
Today`s Open: 0.840 # of Trades: 58


JS200

[js200]

.

http://stockcharts.com/gallery?biohf

JS200

[js200]

04/14/2004 (17:38 ET) TSX Venture Exchange closes at 1,788.89 down 24.66 points - The Canadian Press (AP)
04/14/2004 (09:01 ET) Biotech Holdings readies first production run of Sucanon Diabetes drug - PR Newswire
04/12/2004 (17:58 ET) TSX Venture Exchange closes at 1,872.64 down 12.18 points - The Canadian Press (AP)
04/07/2004 (03:52 ET) StockGrid.com: Stock Watch List for Friday, April 9, 2004: BIOHF, BKYI - M2 Communications
03/31/2004 (09:01 ET) Biotech Holdings finalizes plans for launch of Sucanon diabetes drug in Mexico - PR Newswire


JS200

[js200]

04/22/2004 (09:17 ET) BIOHF: Begins Production of Sucanon for Type II Diabetes - Knobias
04/22/2004 (09:00 ET) Biotech Holdings starts production of Sucanon diabetes drug - PR Newswire
04/16/2004 (16:42 ET) TSX Venture Exchange closes at 1,817.06 up 21.19 points - The Canadian Press (AP)
04/14/2004 (17:38 ET) TSX Venture Exchange closes at 1,788.89 down 24.66 points - The Canadian Press (AP)
04/14/2004 (09:01 ET) Biotech Holdings readies first production run of Sucanon Diabetes drug - PR Newswire


JS200

[js200]

Last Trade: 0.730 Change: 0.010 (+1.389%)
Previous Close: 0.720 Volume: 228,700
Bid: 0.730 Ask: 0.745
Today`s Open: 0.740 # of Trades: 87


JS200

[js200]

BIOHF: Begins Production of Sucanon for Type II Diabetes

Thursday , April 22, 2004 09:17 ET

Biotech Holdings (BIOHF) announced that production of Sucanon is now underway. producing 25,000 one-month treatment packages for the Mexico market. Shipment is scheduled to begin next week. Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients` ability to utilize insulin. has received regulatory approval for sale of the drug in Mexico and Peru as a treatment of Type II Diabetes symptoms.


JS200

[SoWhat]

@Js
Zu Deiner Info:
Bei dem Produkt "Sucanon" handelt es sich um ein Mittel eines chinesischen Herren, der offenbar ein Agreement mit Biotech getroffen hat. Produziert wird es in China.

Good luck

sowhat

[js200]

05/05/2004 (03:36 ET) Wall Street News Alert: OTC Stock Traders Watch! May 5, 2004, Part 3 - M2 Communications
05/03/2004 (09:01 ET) Biotech Holdings makes first shipment of Sucanon diabetes drug - PR Newswire

JS200

[js200]

06/02/2004 (10:57 ET) Wall Street News Alert: Aggressive Traders Alert! June 2, 2004 - M2 Communications
06/02/2004 (04:41 ET) StockGrid.com: Stock Watch Alert for Wednesday, June 2, 2004: TIGR - M2 Communications
06/02/2004 (03:55 ET) StockGrid.com: Stock Watch Alert for Wednesday, June 2, 2004: BIOHF - M2 Communications
06/01/2004 (10:11 ET) BIOHF: Volume Spike; 8% > 20-adsv, Stock +2.00% - Knobias
06/01/2004 (09:01 ET) Biotech Holdings signs Sucanon Marketing agreement for Mexico - PR Newswire

JS200

[js200]

06/07/2004 (07:01 ET) Biotech Holdings completes first Sucanon production order - PR Newswire
06/02/2004 (10:57 ET) Wall Street News Alert: Aggressive Traders Alert! June 2, 2004 - M2 Communications
06/02/2004 (04:41 ET) StockGrid.com: Stock Watch Alert for Wednesday, June 2, 2004: TIGR - M2 Communications
06/02/2004 (03:55 ET) StockGrid.com: Stock Watch Alert for Wednesday, June 2, 2004: BIOHF - M2 Communications
06/01/2004 (10:11 ET) BIOHF: Volume Spike; 8% > 20-adsv, Stock +2.00% - Knobias

JS200

[js200]

Last Trade: 0.560 Change: -0.030 (-5.085%)
Previous Close: 0.590 Volume: 101,100
Bid: 0.550 Ask: 0.590
Today`s Open: 0.590 # of Trades: 36

--------------------------------------------------------------------------------

Day High: 0.590 Day Low: 0.530
52 Week High: 0.930 52 week Low: 0.038
Market Cap: 46.07M Avg Daily Vol: N/A
EPS: -0.02 PE Ratio: -28.000
Dividend: N/A Yield: N/A

JS200

[js200]

06/21/2004 (12:04 ET) BIOHF: Volume Spike; 20% > 20-adsv, Stock -2.13% - Knobias
06/15/2004 (09:33 ET) InvestSource Inc.: Biotech Momentum: PRWM, ONCY, BIOHF, PCOP, PFE - M2 Communications
06/07/2004 (07:01 ET) Biotech Holdings completes first Sucanon production order - PR Newswire
06/02/2004 (10:57 ET) Wall Street News Alert: Aggressive Traders Alert! June 2, 2004 - M2 Communications
06/02/2004 (04:41 ET) StockGrid.com: Stock Watch Alert for Wednesday, June 2, 2004: TIGR - M2 Communications

JS200

[js200]

Last Trade: 0.470 Change: 0.020 (+4.444%)
Previous Close: 0.450 Volume: 15,300
Bid: 0.440 Ask: 0.470
Today`s Open: 0.450 # of Trades: 7


JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


08/30/2004 (08:02 ET) Biotech President looks forward to cash flow from diabetes drug - Canada NewsWire



08/30/2004 (08:01 ET) Biotech President looks forward to cash flow from diabetes drug - PR Newswire



08/27/2004 (11:40 ET) BIOHF: Volume Spike; 21% > 20-adsv, Stock +6.12% - Knobias



08/27/2004 (08:01 ET) Biotech Holdings begins investor awareness program for fall period - Canada NewsWire



08/27/2004 (08:00 ET) Biotech Holdings begins investor awareness program for fall period - PR Newswire



08/19/2004 (11:10 ET) HotStockChat.com: HotStockChat.com Reports on Stocks of Interest and Stocks on the Move for August 19, 2004. - M2 Communications



08/18/2004 (10:55 ET) BIOHF: Volume Spike; 35% > 20-adsv, Stock +11.90% - Knobias



08/18/2004 (08:01 ET) Revenue from Sucanon Diabetes drug to begin, Biotech President says in letter to shareholders - Canada NewsWire



08/18/2004 (08:00 ET) Revenue from Sucanon Diabetes drug to begin, Biotech President says in letter to shareholders - PR Newswire



08/12/2004 (09:07 ET) BIOHF: Announces Sept Launch for Sucanon Diabetes Drug - Knobias



08/12/2004 (09:04 ET) Biotech announces September launch for Sucanon diabetes drug - Canada NewsWire



08/12/2004 (09:01 ET) Biotech announces September launch for Sucanon diabetes drug - PR Newswire



08/05/2004 (09:51 ET) BIOHF: New 52-Wk Low @ $0.340 dn 8.11% - Knobias



08/05/2004 (09:03 ET) Biotech producing increased supply of Sucanon diabetes drug in preparation for Mexico launch - Canada NewsWire



08/05/2004 (09:01 ET) Biotech producing increased supply of Sucanon diabetes drug in preparation for Mexico launch - PR Newswire



08/04/2004 (11:16 ET) BIOHF: New 52-Wk Low @ $0.350 dn 7.89% - Knobias


JS200

[js200]

Last Trade: 0.520 Change: 0.010 (+1.961%)
Previous Close: 0.510 Volume: 42,100
Bid: 0.510 Ask: 0.540
Today`s Open: 0.520 # of Trades: 14


JS200

[js200]

Hält sich sehr wacker

JS200

[js200]

09/10/2004 (11:21 ET) BIOHF: Volume Spike; 12% > 20-adsv, Stock -11.07% - Knobias
08/30/2004 (08:02 ET) Biotech President looks forward to cash flow from diabetes drug - Canada NewsWire
08/30/2004 (08:01 ET) Biotech President looks forward to cash flow from diabetes drug - PR Newswire
08/27/2004 (11:40 ET) BIOHF: Volume Spike; 21% > 20-adsv, Stock +6.12% - Knobias
08/27/2004 (08:01 ET) Biotech Holdings begins investor awareness program for fall period - Canada NewsWire


JS200

[js200]

Last Trade: 0.580 Change: 0.020 (+3.571%)
Previous Close: 0.560 Volume: 13,500
Bid: 0.560 Ask: 0.580
Today`s Open: 0.580 # of Trades: 5

Bei Durchbruch der 0,60 Dollar locken 25---30%

JS200

[js200]

09/21/2004 (12:11 ET) BIOHF: Volume Spike; 24% > 20-adsv, Stock -3.85% - Knobias
09/10/2004 (11:21 ET) BIOHF: Volume Spike; 12% > 20-adsv, Stock -11.07% - Knobias
08/30/2004 (08:02 ET) Biotech President looks forward to cash flow from diabetes drug - Canada NewsWire
08/30/2004 (08:01 ET) Biotech President looks forward to cash flow from diabetes drug - PR Newswire
08/27/2004 (11:40 ET) BIOHF: Volume Spike; 21% > 20-adsv, Stock +6.12% - Knobias

[js200]

10/01/2004 (08:02 ET) Biotech Holdings president provides update on Latin American Operations - Canada NewsWire
10/01/2004 (08:01 ET) Biotech Holdings president provides update on Latin American Operations - PR Newswire
09/22/2004 (16:56 ET) Biotech Holdings opening Latin American sales office in Mexico City - PR Newswire
09/22/2004 (16:56 ET) Biotech Holdings opening Latin American sales office in Mexico City - Canada NewsWire
09/21/2004 (12:11 ET) BIOHF: Volume Spike; 24% > 20-adsv, Stock -3.85% - Knobias

[js200]

Last Trade: 0.450 Change: 0.010 (+2.273%)
Previous Close: 0.440 Volume: 38,400
Bid: 0.430 Ask: 0.450
Today`s Open: 0.430 # of Trades: 10

[js200]

Last Trade: 0.470 Change: 0.000 (+0.000%)
Previous Close: 0.470 Volume: 34,300
Bid: 0.445 Ask: 0.490
Today`s Open: 0.470 # of Trades: 8

[js200]

10/26/2004 (08:03 ET) Biotech Holdings private placement funding to be applied to diabetes drug launch - PR Newswire
10/26/2004 (08:02 ET) Biotech Holdings private placement funding to be applied to diabetes drug launch - Canada NewsWire
10/01/2004 (08:02 ET) Biotech Holdings president provides update on Latin American Operations - Canada NewsWire
10/01/2004 (08:01 ET) Biotech Holdings president provides update on Latin American Operations - PR Newswire

[js200]

Biotech Holdings private placement funding to be applied to diabetes drug launch

Tuesday , October 26, 2004 08:03 ET

VANCOUVER, Oct 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) announced today that the Company has received preliminary regulatory approval to proceed with raising private placement funding totaling $1,000,000 Cdn.

"These funds will be applied to requirements associated with the launch of our diabetes drug, Sucanon, in Mexico including purchase of television and radio time, in-store support for Sucanon and medical presentations," Mr. Rieveley said.

"We have to date received $111,000 of the above private placement funding. Shares pursuant to this funding will be issued at $.50 Cdn, with each share having a two-year warrant exercisable at $.55 Cdn. The U.S. dollar equivalent, for U.S. placees, will be at the current rate of exchange," Mr. Rieveley said.

Sucanon is a new drug for treating symptoms of Type II Diabetes and Impaired Glucose Tolerance. The drug, in tablet form, works by improving patients` ability to utilize insulin, the hormone that controls blood sugar levels. Type II Diabetes affects more than 17 million people in North America and over 20 million in Latin America. In addition, the number of people with Impaired Glucose Tolerance is even larger than the number of diabetics.

Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru and plans to make regulatory applications for the drug for Chile, Venezuela, Columbia, Argentina and Brazil.

If you would you would like to be added to Biotech Holdings` email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp

Biotech Holdings Ltd.`s head office is in Richmond, British Columbia. Biotech Holdings` shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For inquiries, contact Austin Rand at Biotech Holdings Ltd., 1 [phone] (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at [e-mail]. For background information and current stock quotations, please visit Biotech`s website at www.biotechltd.com.





SOURCE Biotech Holdings Ltd.


CONTACT: Austin Rand at Biotech Holdings Ltd., 1 [phone]
(toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at
[e-mail]; For background information and current stock
quotations, please visit Biotech`s website at www.biotechltd.com;
To request a free copy of this organization`s annual report, please go to
http://www.newswire.ca and click on reports@cnw.
(BIO. BIOHF)

http://www.prnewswire.com



Copyright (C) 2004 PR Newswire. All rights reserved.


-0-


KEYWORD: British Columbia
INDUSTRY KEYWORD: MTC
OTC


STOCK SYMBOLS: [(bio.)] [(biohf)]

[js200]

Last Trade: 0.430 Change: 0.030 (+7.500%)
Previous Close: 0.400 Volume: 194,600
Bid: 0.420 Ask: 0.450
Today`s Open: 0.390 # of Trades: 19

[js200]

Last Trade: 0.464 Change: 0.034 (+7.907%)
Previous Close: 0.430 Volume: 0
Bid: 0.430 Ask: 0.470
Today`s Open: N/A # of Trades: N/A

[js200]

Last Trade: 0.450 Change: -0.050 (-10.000%)
Previous Close: 0.500 Volume: 3,500
Bid: 0.350 Ask: 0.450
Today`s Open: 0.450 # of Trades: 2

Schwache Vorstellung, ..................................!!!!!!!!!

JS200